Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Just before the November 4th AMDAC on solithromycin, we are being treated to a very fine piece of study write-up. Of course, we are speaking of the File paper on the SOLITAIRE-IV trial, and what a fine piece of crafty penmanship it is, if you haven’t noticed. Just as a Continue reading Solithromycin SOLITAIRE-IV: So-So Results for a So-So Drug
According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development. So we are in fairly close agreement. That may seem like an impressive record but it is also Continue reading QIDP Drug Update – Part 2: Categories of Interest
It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries. (Status: 10/18/16) Despite best efforts to provide accurate information, errors may have crept in. Please let us know if you detect mistakes. We will make corrections or post Continue reading QIDP Drug Update – Part 1: An Updated Who Is Who